Pancreatic Beta-cell Protection, Hot Targets & Pipeline Analysis

Publishing Date : August, 2016
Report Code : HCMD103
Price:
Single license $3,600
Site license $5,400
Global license $7,200


This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Diabetes Drug market. The report also provides strategic insights on medicines that are likely to have an impact on beta-cell protection treatment space and potentially alter standards of care in the foreseeable future.

Therapies that are presently available for diabetes focus on reducing the disease symptoms, but there is a huge unmet need for therapies that can either slow or prevent the beta cell loss as there is a rapid loss of cells in type 1 diabetes and progressive loss in type 2 diabetes patients

Currently, researchers are focusing on novel therapeutic strategies aimed at restoring, or at least preventing further loss of beta cell mass in beta cell deficit type 1 and type 2 diabetes patients as endogenous secretion of insulin is advantageous over exogenous insulin such as direct effect on hepatic (liver) glucose metabolism. Hence, it provides a tremendous opportunity for upcoming therapies specific to Beta-cell loss such as MAbs, stem cell-based, gene therapies and RNA-based therapies. These modalities may provide beta-cell protection, regeneration, mass increase with additional benefits of weight loss, triglyceride lowering and kidney protection.

  • 1     —REPORT DESCRIPTION
  • 2     —INTRODUCTION-PANCREATIC BETA CELL PROTECTION
    • 2.1     —Diabetes Snapshot & Prevalence
  • 3     —RESEARCH METHODOLOGY
    • 3.1     —Sources
  • 4     —HOT TARGETS-BETA CELL PROTECTION
  • 5     —TARGET ANALYSIS –
    • 5.1     —Top Targets
    • 5.2     —Top University/Company
  • 6     —MOLECULES – BETA CELL PROTECTION
    • 6.1     —Beta Cell Protection Pipeline By Molecule Type
    • 6.2     —Small Molecules Segmentation By Phase
    • 6.3     —Large Molecules Segmentation By Phase
    • 6.4     —Beta Cell Protection Pipeline By Phases
    • 6.5     —Beta Cell Protection Pipeline By Companies
    • 6.6     —Beta cell Protection – Molecules Vs Targets
  • 7     —OTHER TARGETS ON BETA CELL PROTECTION
  • 8     —BETA CELL PROTECTION – DEALS
  • 9     —TARGETS – BETA CELL APOPTOSIS
  • 10     —OTHER TARGETS ON BETA CELL APOPTOSIS